Moderna Inc. ($MRNA) Stock Forecast: Down 5.7% Today

What is Moderna Inc.?

Moderna (MRNA:NASDAQ) is a biotechnology company known for its mRNA technology, particularly in the development of vaccines and therapies.

Why is Moderna Inc. going down?

MRNA stock is down 5.7% on Jan 30, 2026 19:10

• Moderna's stock experienced a bearish movement following the announcement of the departure of its chief medical officer amidst other executive departures within the company.
• The appointment of Dr. David Berman as the new Chief Development Officer was not enough to offset the negative sentiment, as investors may be concerned about the leadership changes and potential impact on the company's future direction.
• The partnership with Recordati to develop an mRNA therapy for a rare metabolic disorder was a positive development, but it seems the market focused more on the internal leadership changes at Moderna.
• The overall market reaction suggests that investors are closely monitoring Moderna's executive team transitions and the company's ability to maintain its innovative edge in mRNA technology amidst leadership shake-ups.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna announces departure of medical chief (MRNA:NASDAQ)

Moderna announced that its chief medical officer, Jacqueline Miller, will resign effectively March 2nd, a little over a year after assuming the role. This news follows previous departures within the company's executive ranks. The company will look to fill this critical leadership position.

https://seekingalpha.com/news/4544945-moderna-announces-departure-medical-chief

Dr. David Berman to Join Moderna as Chief Development Officer

Moderna, Inc. announced the appointment of Dr. David Berman as its new Chief Development Officer, effective March 2, 2026. Dr. Berman brings over two decades of experience in oncology and infectious disease development, having held leadership roles at Immunocore, AstraZeneca, and Bristol-Myers Squibb. He will join Moderna's Executive Committee, while Dr. Jacqueline Miller will transition from her Chief Medical Officer role to a consultant position.

https://www.usatoday.com/press-release/story/24748/dr-david-berman-to-join-moderna-as-chief-development-officer/

Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M

Moderna has partnered with Italy's Recordati in a deal worth up to $160 million to develop mRNA-3927, an mRNA therapy for the rare metabolic disorder propionic acidemia (PA). Moderna will maintain control over clinical development and manufacturing, while Recordati will handle commercialization, including an upfront payment of $50 million and potential milestone payments. This collaboration comes as Moderna faces financial pressures, aiming for profitability by 2028 amidst declining COVID-19 vaccine sales.

https://www.biospace.com/deals/moderna-teams-with-recordati-on-rare-disease-mrna-therapy-for-up-to-160m

Moderna appoints David Berman as new chief development officer

Moderna has appointed David Berman, M.D., Ph.D., as its new Chief Development Officer, effective March 2, 2026. Berman, who has extensive experience in immunotherapy development, will join the Executive Committee and report to CEO Stéphane Bancel. This appointment comes as Moderna navigates financial challenges, despite recent stock growth and strategic partnerships.

https://www.investing.com/news/company-news/moderna-appoints-david-berman-as-new-chief-development-officer-93CH-4475847

Dr. David Berman to Join Moderna as Chief Development Officer

Moderna, Inc. announced that Dr. David Berman will join as the company's Chief Development Officer, effective March 2, 2026. He will report to CEO Stéphane Bancel and focus on advancing Moderna's mRNA medicine pipeline across various diseases. Dr. Jacqueline Miller will step down as Chief Medical Officer but will remain as a consultant for the transition.

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/dr.-david-berman-to-join-moderna-as-chief-development-officer-1131969

Trending Today

Bitcoin ($BTC) Crypto Forecast: Down 5.9% Today

Moderna Inc. Price History

30.00.2026 - MRNA Stock was down 5.4%

• A recent partnership for the development of mRNA-3927 for propionic acidemia highlights Moderna's dedication to broadening its portfolio beyond vaccines.
• The appointment of Dr. David Berman as Chief Development Officer brings valuable expertise in immunotherapy, potentially indicating a shift towards advancing clinical-stage therapies.
• Despite recent positive developments, concerns over financial pressures and an ambitious profitability target set for 2028 have led to a bearish market reaction.
• Investors may be cautious about the leadership transition from Dr. Jacqueline Miller to Dr. David Berman, as such changes can introduce uncertainties impacting stock performance.

30.00.2026 - MRNA Stock was down 5.7%

• Moderna's stock experienced a bearish movement following the announcement of the departure of its chief medical officer amidst other executive departures within the company.
• The appointment of Dr. David Berman as the new Chief Development Officer was not enough to offset the negative sentiment, as investors may be concerned about the leadership changes and potential impact on the company's future direction.
• The partnership with Recordati to develop an mRNA therapy for a rare metabolic disorder was a positive development, but it seems the market focused more on the internal leadership changes at Moderna.
• The overall market reaction suggests that investors are closely monitoring Moderna's executive team transitions and the company's ability to maintain its innovative edge in mRNA technology amidst leadership shake-ups.

27.00.2026 - MRNA Stock was up 6.0%

• MRNA stock experienced a bullish movement today.
• The positive market sentiment towards MRNA could be attributed to recent advancements in personalized cancer vaccines by another company, potentially boosting confidence in the biotech sector.
• Additionally, positive developments in the biotech industry, such as progress with a therapy for bladder cancer by another company, may have created a ripple effect of optimism among investors, benefiting companies like MRNA.
• Overall, the growing interest and potential breakthroughs in the biotech field seem to have contributed to the bullish movement in MRNA stock today.

27.00.2026 - MRNA Stock was down 5.2%

• Moderna (MRNA) underwent a period of bearish movement, potentially influenced by positive developments and growth projections of major competitors in the oncology market, including Merck (MRK), Oncolytics Biotech Inc. (ONCY), and other industry participants.
• Merck's (MRK) anticipated rise in earnings and revenues, progress in its oncology pipeline, and revised growth forecasts might have redirected investor attention from Moderna, leading to a decline in its stock performance.
• Analysts' call for enhanced clarity on long-term growth prospects at Merck, despite its notable performance, may have prompted investor apprehensions regarding Moderna's competitiveness and future growth trajectory in biotechnology.
• References to AI stocks presenting superior upside potential compared to Merck could have shifted investor focus towards alternative investment options, thereby contributing to the downward trend in Moderna's stock value.

23.00.2026 - MRNA Stock was down 10.9%

• The stock's decline may have been driven by profit-taking by investors following a recent 4% rally linked to positive five-year follow-up data for their mRNA cancer vaccine in collaboration with Merck.
• Concerns about potential competition or market positioning for Moderna in the oncology sector could have arisen with the amendment of the license agreement between Terns Pharmaceuticals and Hansoh for TERN-701 rights.
• Investor focus and capital might have been redirected towards the banking sector, particularly awaiting Itaú Unibanco's Q4 results, contributing to Moderna's downward trend.
• Despite the promising long-term prospects in oncology, external factors and short-term market dynamics possibly influenced the bearish performance today.

23.00.2026 - MRNA Stock was down 9.4%

• Moderna's stock saw a strong bearish movement possibly due to the announcement of limiting investment in new late-stage vaccine trials, reflecting concerns over achieving returns amidst regulatory hurdles and opposition in the US market.
• The groundbreaking five-year follow-up data for their mRNA cancer vaccine, which demonstrated positive results in high-risk melanoma patients, might have been overshadowed by the decision to curb vaccine trial investments, leading to investor uncertainty.
• The amended license agreement with Hansoh for TERN-701 by Terns Pharmaceuticals could have also impacted Moderna's stock negatively, as it potentially shifts focus and resources away from certain therapeutic products.
• Overall, the market may be reacting to the shifting priorities and strategies within Moderna, as it navigates challenges in the regulatory landscape and transitions towards personalized cancer treatments, impacting investor sentiment and stock performance.

23.00.2026 - MRNA Stock was down 10.7%

• The stock's decline could be attributed to profit-taking or concerns about vaccine distribution challenges.
• Positive updates on Lucid Group, Materion Corp, and Terns Pharmaceuticals might have shifted investor focus away from Moderna.
• Other companies' positive news and Itaú Unibanco's upcoming investor meeting could have added to the downward pressure on Moderna's stock.
• Despite today's bearish movement, Moderna's long-term outlook remains optimistic due to its crucial role in the pandemic response and continuous vaccine innovations.

28.00.2026 - MRNA Stock was down 8.4%

• An analyst initiated coverage on Moderna with an "equal weight" rating and a $25.00 price target, indicating a significant downside potential from its current price. This negative sentiment from analysts likely contributed to the bearish movement.
• The weak fundamentals of Moderna, such as negative EPS and revenue declines, could have further fueled investor concerns and led to the sell-off.
• The lack of growth in revenue and poor financial outlook for biotech companies like BioNTech SE, may have cast a shadow on Moderna's prospects, impacting its stock performance.
• Overall, the combination of negative analyst ratings, weak financial fundamentals, and broader industry concerns about revenue growth in the biotech sector likely contributed to Moderna's bearish market movement today.

22.00.2026 - MRNA Stock was up 10.6%

• Moderna's bullish movement today could be attributed to positive sentiment surrounding the broader biotech sector and the company's ongoing efforts in vaccine development.
• The bullish market movement may also be influenced by the news of Bristol Myers partnering with Janux Therapeutics to develop novel tumor-activated therapeutics, highlighting the potential for innovative approaches in the healthcare industry.
• Additionally, the strong performance of other healthcare companies like Liquidia Technologies hitting an all-time high could have created a positive ripple effect in the sector, boosting investor confidence in Moderna's growth prospects.
• Overall, Moderna's bullish trend today seems to be driven by a combination of sector-wide optimism, positive developments in the healthcare industry, and potentially favorable market conditions for biotech companies.

22.00.2026 - MRNA Stock was up 8.2%

• Moderna's stock surged by 4% following the groundbreaking five-year follow-up data for their mRNA cancer vaccine, showing a significant reduction in the risk of relapse or death in high-risk melanoma patients. This success not only boosted investor confidence in Moderna's technology but also solidified its position as a major player in oncology.
• The announcement of Moderna curbing investments in vaccine trials due to US backlash had a positive impact on the stock, with shares jumping by 10.16% in morning trading. This strategic shift towards personalized cancer treatments in response to regulatory hurdles demonstrates the company's adaptability and focus on long-term growth.
• The partnership between Bristol Myers Squibb and Janux Therapeutics in developing novel T cell engagers for solid tumors may have indirectly contributed to Moderna's bullish movement by highlighting the potential in oncology treatments, further fueling optimism in the biotech sector.
• Overall, Moderna's bullish market movement today can be attributed to its groundbreaking cancer vaccine data, strategic shift towards personalized treatments, and positive investor sentiment towards advancements in oncology therapies.

29.00.2026 - MRNA Stock was up 5.0%

• Moderna's bullish movement could be attributed to positive sentiment surrounding its ongoing developments and potential in the healthcare sector.
• The reduction in stake by Federated Hermes Inc. and director Noubar Afeyan might have initially raised concerns, but the market likely focused more on the broader positive outlook for the company.
• The strong performance of healthcare stocks in the past month, including Moderna, reflects investor confidence in the sector, further boosting MRNA's upward momentum.
• With the focus on NLRP3 inhibitors by other companies like Eli Lilly and BioAge Labs, the overall excitement and advancements in healthcare innovation could have positively influenced Moderna's stock performance.

29.00.2026 - MRNA Stock was up 5.7%

• Moderna's stock soared as investors exhibited confidence in the company's innovative mRNA technology and its promising prospects for growth.
• The decision by Federated Hermes Inc. and director Noubar Afeyan to reduce their stake may have sparked some initial market uncertainty, but the prevailing sentiment leaned towards positivity.
• The stock's remarkable performance could also be linked to its inclusion in the top healthcare stocks list, showcasing its resilience and growth potential in the sector.
• The increased market interest in healthcare stocks, evident from the leading ETFs and the focus on NLRP3 inhibitors by other entities, likely contributed to the further elevation of Moderna's stock price.